What is the future of microRNA technology?

LungCancer+miRNA_700x233

Technology for profiling of microRNA by qPCR is ever evolving, opening up the opportunity for deeper insights into gene regulation. The development of locked nucleic acids (LNA), for example, enhanced qPCR primer specificity, while the design for an effective reverse transcription method for plant microRNAs opened up a new phylogenetic kingdom for qPCR profiling. Developing assays to cover the most recent version of miRBase, expanding to multiple animal models and optimizing total RNA isolation from tricky samples like FFPE and serum and plasma are also important advances in qPCR miRNA detection platforms. With the advent of small RNA sequencing, qPCR also moves into an important role as a validation tool for microRNA sequencing data.

Researchers and companies are continuously searching for ways to improve existing miRNA detection technology, both in terms of performance parameters and flexibility of content. This year, QIAGEN and Exiqon will team up to combine the two of the top-performing microRNA qPCR systems on the market, miScript and miRCury, into one product line with the best attributes of both. But we need your help. We’re creating this new system specifically to meet the needs of microRNA researchers, so it’s crucial to our mission to fully understand and integrate what you want for your studies. Help us create the future of miRNA profiling technologies.

Tell us what you need in our microRNA technology survey!

miRNA_RISC_Ribosomes_SurveyButton_580x200

After you finish the survey, bookmark this space – we’ll be adding links to future posts here that expand on important topics in microRNA detection technology and the future of miScript and miRCury. Stay tuned!

Ali Bierly

Ali Bierly, PhD is a Global Market Manager in Translational Sciences at QIAGEN, and has written on a number of scientific topics in the biotech industry as the author of QIAGEN's Reviews Online. She received her PhD from Cornell University in 2009, studying the immune response to a protozoan parasite, Toxoplasma gondii. Ali has a keen interest in the emerging importance of microRNA and other circulating nucleic acids as biomarkers for disease.

Your email address will not be published. Required fields are marked *